Combining 177Lu-PSMA-617 with ADT Plus ARPI Prolongs rPFS in Patients with PSMA-positive Metastatic Androgen Pathway Modulator-Naive/Sensitive Prostate Cancer By Ogkologos - August 17, 2026 50 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PSMAddition study Source RELATED ARTICLESMORE FROM AUTHOR Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy Continues to Prolong EFS and OS in Patients with Stage II, IIIA, or IIIB (N2) NSCLC Patient Guide in Soft Tissue Sarcoma Now Available Also in Ukrainian Adjuvant Pembrolizumab Continues to Demonstrate Benefit in DFS and OS Among Patients with ccRCC MOST POPULAR Spurred by Survivors, Researchers Are Revisiting Cancer Drug Doses June 5, 2024 Telephone-Based Rehab Program Helps People with Advanced Cancer Maintain Independence April 29, 2019 New on NCI Websites for October 2018 October 30, 2018 Bowel scope screening to stop in England January 14, 2021 Load more HOT NEWS Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α Want to learn more about Sulforaphanes? ESMO World Congress on Gastrointestinal Cancer 2021, 30 June – 3... ctDNA-Guided Therapy with Pertuzumab plus Trastuzumab for HER2-Amplified mCRC
